Ivermectine Pierre Fabre

Ivermectin, the active ingredient in Ivermectine Pierre Fabre, is an anthelmintic presented as an oral dosage form for systemic use. It is employed to treat a range of parasitic infections, including onchocerciasis, strongyloidiasis, scabies, lymphatic filariasis and other helminthic diseases in both adults and children as prescribed by a healthcare professional.

GNH USA supplies Ivermectine Pierre Fabre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin acts on a broad spectrum of parasitic organisms, interrupting their neuromuscular function.

Onchocerciasis: eliminates microfilariae to prevent skin and eye disease. Strongyloidiasis: eradicates intestinal larvae to resolve chronic infection. Scabies: kills Sarcoptes mites, relieving itching and skin lesions. Lymphatic filariasis: reduces adult worm burden to control disease transmission. Other helminth infections: treats various nematode infestations as indicated.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Mild itching or rash at the site of infection. - Nausea or abdominal discomfort. - Diarrhea. - Dizziness or headache. - Transient fever.

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome. - Neurological signs including seizures or altered consciousness. - Hepatotoxicity with elevated liver enzymes. - Visual disturbances. - Severe hypotension.

Before initiating therapy, consider the following precautions.

Pregnancy: Use only if the potential benefit outweighs the risk, as safety data are limited. Breastfeeding: Caution advised; consult a healthcare professional. Co‑administration with other antiparasitics: Monitor for additive toxicity. Renal or hepatic impairment: Dose adjustment may be required under medical supervision. Drug interactions: Review concomitant medications for potential interactions. Store at ambient temperature: Keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Ivermectin may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin) that may reduce efficacy. - Concomitant use with other neurotoxic agents increasing risk of CNS effects.

Moderate Interactions (Monitor Closely): - Anticoagulants: may enhance anticoagulant effect. - P‑glycoprotein inhibitors: could increase ivermectin plasma levels. - Other antiparasitic agents: assess cumulative toxicity.